1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BetterLife Pharma Inc.

BetterLife Pharma Inc.

BETR.CN
BetterLife Pharma Inc.CA flagCanadian Securities Exchange
0.06
CAD
- -
- -
9.11MMarket Cap
BetterLife Pharma Inc.
BETR.CN
(Canadian Securities Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.08
0.42
0.1
-0.16
-1.24
-1.85
-1.09
-0.01
-1.03
-1.3
-1.34
-0.16
-0.1
-0.03
-0.03
-0.01
-0.01
Basic EPS, GAAP
-0.04
-0.04
-0.01
-0.01
-0.05
-0.03
-0.06
-0.07
-0.62
-0.56
-0.27
-0.15
-0.02
-0.02
-0.02
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.07
-0.35
-0.24
-0.56
-4.4
-2.58
-3.58
-1.97
-1.52
-1.14
-1.01
-0.37
-0.41
-0.34
-0.31
-0.26
-0.27
Book Value per Share
-1.05
-0.3
-0.19
-0.16
-0.06
-0.06
-0.26
-0.04
-0.54
0.12
-0.17
-0.05
-0.09
-0.07
-0.06
-0.04
-0.04
Tangible Book Value per Share
3
3
4
5
1
8
8
8
9
15
27
75
87
109
124
146
136
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
1
- -
-1
-1
-14
-8
- -
-9
-20
-36
-12
-9
-3
-4
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-1
-1
-1
- -
- -
-2
- -
-5
3
-5
-3
-7
-7
-7
-6
-6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
5
- -
1
- -
1
- -
- -
- -
LT Debt
-3
-1
-1
-1
- -
- -
-2
- -
3
3
-5
-4
-8
-8
-7
-6
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-87.46
-42.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.81
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'25
Apr'26
Jul'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
130
145
152
Market Capitalization
16
11
12

Working Capital

FRC

•

in mil. unless spec.
Jan'25
Apr'26
Jul'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
6
6
Payables & Accruals
6
5
5
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-637.57%
12.83%
-11.9%
Free Cash Flow
99.69%
-11.03%
-69.06%
Net Income, GAAP
2,160.99%
-39.21%
-57.52%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
- -
- -
-0.03
2025
-0.02
-0.01
- -
- -
-0.03
2026
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Quantum-Si incorporated (QSIAW)
Scinai Immunotherapeutics Ltd. (SCNI)
Gritstone bio, Inc. (GRTS)
Karyopharm Therapeutics Inc. (KPTI)
Vaxcell-Bio Therapeutics Co., Ltd. (323990.KQ)
Galapagos N.V. (GLPG)
Business
BetterLife Pharma Inc. (CSE:BETR) is a biotechnology company focused on developing and commercializing non-hallucinogenic psychedelic derivatives and related compounds to treat neuro-psychiatric, neurological disorders and viral infections. The company offers BETR-001 (2-bromo-LSD or E559), a proprietary oral capsule second-generation LSD derivative in IND-enabling studies for major depressive disorder, anxiety disorder, neuropathic pain, treatment-resistant depression, PTSD, cluster headaches, traumatic brain injury and migraines; BETR-002 (dihydrohonokiol-B or DHH-B), an oral capsule derivative of hydrohonokiol targeting benzodiazepine dependency, anxiety and neurodegenerative disorders; and interferon-based candidates including MM-003, which completed Phase II trials for COVID-19 and respiratory viral infections, and MM-001, a topical cream that completed Phase II trials for HPV-induced cervical intraepithelial neoplasia, through its wholly owned subsidiary MedMelior Pharmaceuticals Inc. BetterLife Pharma Inc. was founded in 2002, changed its name from Pivot Pharmaceuticals Inc. in December 2019, and maintains headquarters at 1275 West 6th Avenue, Suite 300, Vancouver, British Columbia, Canada V6H 1A6. The company conducts operations and strategic relationships in Canada, the United States and Switzerland, with common shares listed on the Canadian Securities Exchange, OTCQB and Frankfurt exchanges. Recent developments include closing private placements and convertible debentures totaling approximately $1.168 million to advance BETR-001 development; appointing Daniel Carcillo, a traumatic brain injury survivor and advocate, as corporate advisor on November 25, 2025, to support BETR-001 indications in TBI, cluster headaches and migraines; and advancing IND-enabling studies and presentations at conferences such as the 2024 Bloom Burton & Co. Healthcare Investor Conference.

Company News

APIChat

  • feeds.newsfilecorp.com

    BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director